Castle Biosciences CSTL EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Castle Biosciences’s reported figures.
Based on trailing twelve months.
The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Castle Biosciences's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Castle Biosciences's EBITDA margin?
- Castle Biosciences (CSTL) reported EBITDA margin of -5.4% in Q1 2026.
- How has Castle Biosciences's EBITDA margin changed year-over-year?
- Castle Biosciences's EBITDA margin decreased by 165.4% year-over-year, from 8.2% to -5.4%.
- What is the long-term trend for Castle Biosciences's EBITDA margin?
- Over 5 years (2020 to 2025), Castle Biosciences's EBITDA margin has grown at a -42.8% compound annual growth rate (CAGR), from -9.7% to -0.6%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.